Mechanisms of neuromodulation as dissected using Sr2+ at motor nerve endings.
The use of binomial analysis as a tool for determining the sites of action of neuromodulators may be complicated by the nonuniformity of release probability. One of the potential sources for nonuniformity of release probability is the presence of multiple forms of synaptotagmins, the Ca2+ sensors responsible for triggering vesicular exocytosis. In this study we have used Sr2+, an ion whose actions may be restricted to a subpopulation of synaptotagmins, in an attempt to obtain meaningful estimates of the binomial parameters p (the probability of evoked acetylcholine [Ach] release) and n (the immediate available store of ACh quanta, whereby m = np). In contrast to results in Ca2+ solutions, binomial analysis of Sr2+-dependent release reveals a dramatically reduced dependence of n on extracellular Sr2+ concentrations. In Sr2+ solutions, blockade of potassium channels with 3,4-diaminopyridine increased m by an exclusive increase in p, whereas treatment with phorbol ester increased m solely by effects on n. The cyclic adenosine monophosphate (cAMP) analogue CPT-cAMP increased m by increasing both n and p. The effect of CPT-cAMP on p but not on n was blocked by protein kinase A (PKA) inhibitors, whereas the effect on n was mimicked by 8-CPT-2'-O-Me-cAMP, a selective agonist for exchange protein directly activated by cAMP, otherwise known as the cAMP-sensitive guanine nucleotide-exchange protein. The results demonstrate both the utility of the binomial distribution in Sr2+ solutions and the dual effects of cyclic AMP on both PKA-dependent and PKA-independent processes at the amphibian neuromuscular junction.
Searl
Timothy J
TJ
Department of Molecular Pharmacology and Biological Chemistry, Northwestern University Medical School, Chicago, IL 60611, USA. tjs026@northwestern.edu
Silinsky
Eugene M
EM
D015761:4-Aminopyridine / Q000031:analogs & derivatives / Q000494:pharmacology; D000077770:Amifampridine; D000818:Animals; D002118:Calcium / Q000378:metabolism; D002227:Carbazoles / Q000494:pharmacology; D000242:Cyclic AMP / Q000031:analogs & derivatives / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005071:Evoked Potentials / Q000502:physiology / Q000528:radiation effects; D066298:In Vitro Techniques; D009411:Nerve Endings / Q000187:drug effects* / Q000502:physiology*; D009469:Neuromuscular Junction / Q000166:cytology*; D018377:Neurotransmitter Agents / Q000378:metabolism; D026902:Potassium Channel Blockers / Q000494:pharmacology; D011758:Pyrroles / Q000494:pharmacology; D011898:Ranidae; D018709:Statistics, Nonparametric; D013324:Strontium / Q000494:pharmacology*; D013873:Thionucleotides / Q000494:pharmacology
D002227:Carbazoles; D004791:Enzyme Inhibitors; D018377:Neurotransmitter Agents; D026902:Potassium Channel Blockers; D011758:Pyrroles; D013873:Thionucleotides; C015929:8-((4-chlorophenyl)thio)cyclic-3',5'-AMP; C057416:KT 5720; D015761:4-Aminopyridine; D000242:Cyclic AMP; D000077770:Amifampridine; D002118:Calcium; D013324:Strontium